Recombinant Human Endosialin/CD248 Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Endosialin, also known as TEM1 (tumor endothelial marker 1) and designated CD248, is a 165‑175 kDa type I transmembrane O‑glycosylated protein that is expressed on activated perivascular and stromal cells in embyronic and tumor neovasculature, but down‑regulated in quiescent vasculature (1‑4). The human Endosialin cDNA encodes 757 amino acids (aa) including a 17 aa signal sequence, a 670 aa extracellular domain (ECD) with one C‑type lectin, one Sushi, one EGF‑like domain and a mucin-like stalk, a transmembrane sequence, and a short (49 aa) cytoplasmic domain with three potential phosphorylation sites and a PDZ binding motif (2, 3). Within the ECD, human Endosialin shares 76% and 74% aa sequence identity with mouse and rat Endosialin, respectively. Endosialin regulates pericyte proliferation, migration, and adhesion to endothelial cell‑deposited fibronectin and collagens I and IV in the extracellular matrix (3‑7). It binds Galectin‑3/MAC‑2BP, mediating a repulsive signal thought to guide tumor cell migration (5). In blood vessel development, it promotes endothelial cell apoptosis and pruning of unwanted capillaries (6). In humans, it is up‑regulated on mesenchymal stem cells, naïve CD8⁺ T cells, and leukocytes that express markers of endothelial and dendritic lineages (3, 8). It is dynamically expressed on lymphoid tissue stromal cells and is required for lymph node, spleen, and thymus remodeling during immune responses (8‑11). Its expression correlates with suppressed proliferation of human naïve CD8⁺ T cells, and with aggressiveness of some tumors (8, 12, 13). Endosialin expression is up‑regulated in vitro by high cell density and hypoxia (3, 14). Inflammatory conditions such as rheumatoid and psoriatic arthritis and IgA nephropathy can cause expression in stroma that do not normally express Endosialin (3).

We have publications tested in 1 confirmed species: Mouse.

We have publications tested in 1 application: Bioassay.

Showing Publications 1 - 2 of 2.

Publications using 7855-CD	Applications	Species
CH Pai, SR Lin, CH Liu, SY Pan, H Hsu, YT Chen, CT Yen, IS Yu, HL Wu, SL Lin, SW Lin Targeting fibroblast CD248 attenuates CCL17-expressing macrophages and tissue fibrosis Sci Rep, 2020-10-08;10(1):16772. 2020-10-08 [PMID: 33033277] (Bioassay, Mouse)	Bioassay	Mouse
E Capone, E Piccolo, I Fichera, P Ciufici, D Barcaroli, A Sala, V De Laurenz, V Iacobelli, S Iacobelli, G Sala Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma Oncotarget, 2017-07-22;8(36):60368-60377. 2017-07-22 [PMID: 28947977] (Bioassay)	Bioassay

Array 7855-CD

• Endosialin/CD248/TEM1 Antibodies
• Endosialin/CD248/TEM1 Lysate
• Endosialin/CD248/TEM1 Proteins
• Endosialin/CD248/TEM1 Proteins and Enzyme